or 27.27 percent decreased by following details; Cost of goods sold as amount of 282.16 Million Baht as 99.25 Million Baht decreased or 26.02 percent when compared to same period of previous year of
Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 3-Month Period Ending March 31st 2020 2019 Change MB % MB % MB % Cost of Sales 35.76
December 2022 until 26 January 2023. The Thailand Taxonomy Phase I focuses on the economic activities relating to the energy and transportation sectors, which contribute to the highest proportion of carbon
expediting launch of infrastructure funds.? Today?s discussion also covered possibilities for setting infrastructure funds to support development of national transportation systems. ?The Ministry of Transport
to achieve COD as scheduled in PPA, and construction cost is in line with the budget approved by lenders. This achievement would enable us to keep record of managing the project to commence COD in time
term. In addition to achieving revenue growth, the company-wide cost optimization is ongoing and translated into EBITDA expansion of +9% YoY and +2.4% QoQ to stand at Bt18,905mn, a reported margin of
million. Total expenses increased by Baht 640 million as compared to last year mainly due to the following: Cost of hotel operations decreased by Baht 42 million which is in line with the lower hotel
) Consolidated * 2018 2017 Increase / (Decrease) % Change Revenues from sales 666.36 387.35 279.01 103.38% Other revenues 6.76 1.21 5.54 458.11% Total revenues 673.12 388.56 284.55 73.23% Cost of sales 256.50
% 100.00% Cost of sales (48.06 ) (37.80 ) (10.26 ) 27.14% (71.23%) (66.95%) Gross Profit 19.41 18.66 0.75 4.02% 28.77% 33.05% Other income 2.78 1.66 1.12 67.47% 4.12% 2.94% Gain on disposal of investment
stated ) Q1 2017 Q1 2016 Change Amount % Total Revenues 3,946 3,910 36 0.9% Sales and service income 3,829 3,818 8 0.2% Other income 117 92 25 27.9% Cost of sales and services 3,533 3,550 (17) -0.5% SG&A